You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Incruse Ellipta is an inhalation powder used to treat chronic obstructive pulmonary disease (COPD) in adults. Incruse Ellipta contains an active substance called umeclidinium bromide, which belongs to a group of medicines called bronchodilators.

What is COPD?

Discover more about COPD, including characteristics, symptoms and causes

Read more

Patient information

Information specifically for patients who have been prescribed Incruse Ellipta

Read more

Safety information

For further information on Incruse Ellipta, including information on warning and precautions for use and any potential side effects, please see the Incruse Ellipta patient information leaflet. This link will take you to the medicines.ie website website which is a non-GSK website.

Incruse Ellipta PIL

Further information

Find links to professional organisations, charities and other useful websites for COPD

Further information

▼These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting side effects you may get.

If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via HPRA Pharmacovigilance, Website: www.hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine.

Incruse Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies